Core Insights - HeartFlow is a software company that utilizes AI for the diagnosis, treatment, and management of coronary artery disease [2] - The company was founded in 2010 and received its first FDA clearance in 2014 [2] Market Overview - HeartFlow targets the symptomatic market for coronary artery disease, estimating a total addressable market (TAM) of $5 billion [3] - As of 2025, HeartFlow has established an installed base of 1,465 accounts in the U.S., defined as hospitals or clinics with coronary CCTA imaging capabilities [3]

Siemens Healthineers FY Conference Summary Company Overview - Siemens Healthineers is a market leader in imaging and precision therapy, with 90% of academic medical centers as clients [2][3] - The company operates in 70 countries with an installed base of approximately 700,000 systems and 3 billion patient touchpoints annually [3] - R&D investment exceeds EUR 2 billion, with 13,000 employees dedicated to innovation [3] Market Position and Performance - Siemens Healthineers holds a 38% market share in imaging, an increase of 7 percentage points since its IPO [4] - Varian's market share has grown by 10 percentage points to over 60% since the acquisition [4] - The company has an order backlog of EUR 6 billion from large value partnerships [3] Strategic Focus - The company aims to address non-communicable diseases (NCDs) such as cancer and cardiovascular diseases through early detection and personalized treatment [5][6] - Key pillars include patient imaging, precision therapy, and healthcare AI to enhance treatment personalization [6] Imaging and Technology Innovations - Strong presence in MRI with over 50% market share in the U.S. [6] - Photon Counting CT technology is a flagship innovation, expected to revolutionize cardiac disease management [8][27] - The distribution business of radiopharmaceuticals (PETNET) is projected to reach EUR 1 billion [8] Financial Performance and Outlook - The company expects revenue growth of 5%-6% for the fiscal year, with adjusted EPS between EUR 2.20 and EUR 2.40 [19][20] - Anticipated headwinds include foreign exchange impacts and tariffs, totaling EUR 0.30 per share [20] - Long-term growth targets include 6%-9% annual growth in core imaging and precision therapy segments starting in 2027 [22] Capital Allocation and Shareholder Value - Siemens Healthineers has a stable and growing dividend policy, with a commitment to deleverage from 2.8 times to 2.5 times net debt over EBITDA in the next 24 months [18] - The company aims for a cash conversion rate of 0.8-0.9 annually, with a focus on maintaining strong free cash flow [17] Challenges and Market Dynamics - The company faces challenges in the Chinese market, with expectations of flat growth in the near term [24][25] - Increased competition and local government support for domestic players are noted concerns [25] - The diagnostics segment is being restructured for operational independence, with no immediate plans for divestiture [27] Conclusion - Siemens Healthineers is well-positioned for future growth through its strong market presence, innovative technologies, and strategic focus on addressing critical healthcare needs. The company is committed to enhancing shareholder value while navigating market challenges and optimizing its operational structure.

HeartFlow (NasdaqGS:HTFL) FY Conference Summary Company Overview - HeartFlow is a software company utilizing AI for the treatment, diagnosis, and management of coronary artery disease, founded in 2010 with FDA clearance in 2014 [1][2] - The company targets the symptomatic market, estimating a total addressable market (TAM) of $5 billion [2] Key Financial Performance - In 2025, HeartFlow added 340 new accounts, reaching a total of 1,465 accounts, marking the best fiscal year for account additions [2] - Trailing 12 months revenue reached $162 million, reflecting a 41% growth [3] - Strong Q4 performance with no negative surprises, exceeding consensus expectations [3][4] Product and Technology Developments - HeartFlow has developed the world's largest proprietary database of coronary CCTA images, with over 160 million annotated images [3] - The company is expanding its product offerings with plaque analysis, currently live in 489 accounts, with a goal of over 1,000 accounts by the end of 2026 [4][26] - New randomized controlled trials (RCTs) will be initiated in 2026 to expand into the asymptomatic market [4][34] Clinical Evidence and Market Position - HeartFlow has over 600 peer-reviewed publications supporting its clinical evidence [3] - The company aims to create a new standard of care in coronary artery disease, currently having less than 2% market penetration [9][32] - The company’s AI-driven approach is compared to advancements in cancer diagnostics, emphasizing improved accuracy and patient outcomes [8][9] Growth Strategy - HeartFlow's strategy involves starting with the most diseased patients and gradually moving to less urgent cases, including asymptomatic patients [9][34] - The company plans to leverage its existing technology to enter the asymptomatic market, targeting a TAM of $6 billion [34] Market Dynamics and Competition - HeartFlow faces competition from the current standard of care, which is deemed inaccurate [5][32] - The company is focused on educating the market and driving adoption of its plaque analysis technology [40][42] Financial Outlook - HeartFlow aims for profitability within three years post-IPO, targeting 2028 for cash flow break-even [47] - The company expects continued revenue growth driven by its subscription model and expansion into new markets [48] Coverage and Reimbursement - Over 70% of lives are covered for plaque analysis, with a Category I CPT code in place [13][28] - The company is actively working with payers to expand coverage based on clinical data from its DECIDE registry [27][43] Conclusion - HeartFlow is positioned for significant growth with a strong focus on clinical evidence, market education, and expanding its product offerings in the coronary artery disease space [37][48]

Core Viewpoint - GE HealthCare is focused on transforming healthcare by addressing significant challenges and enhancing patient care through innovative solutions [2][3]. Group 1: Company Overview - GE HealthCare is entering its fourth year as a separate public company, emphasizing a vision of limitless healthcare [2]. - The company aims to evolve from a world-class imaging company to a comprehensive healthcare solutions provider [3]. Group 2: Strategic Focus - The company's strategy is built on three pillars: precision care, growth acceleration, and business optimization [3]. - Precision care involves delivering more targeted and effective individual care solutions, particularly in imaging, diagnostics, and therapeutics [3]. - Growth acceleration is centered on enhancing product offerings to drive faster growth [4].

Company Overview - Insulet's vision is to create a world where diabetes demands less every day, everywhere, reflecting a commitment to transforming the lives of people with diabetes [3] - The company's mission is driven by empathy, ingenuity, and proven science, emphasizing its dedication to improving diabetes management [3] Product Impact - The introduction of Omnipod 5 has significantly improved patient outcomes, as demonstrated by a case study where a user named Eric experienced a drop in A1c from 7.5% to 6.5% and increased time in range to 90% after using the product [4]

Core Insights - DexCom is recognized as a pioneer in the Continuous Glucose Monitoring (CGM) industry, having introduced several groundbreaking innovations that have transformed diabetes management [2]. Group 1: Innovations and Impact - DexCom was the first to introduce a real-time hypoglycemia alert system in CGM technology, significantly enhancing patient safety [2]. - The company developed the first CGM with a remote monitoring system, allowing caregivers to monitor patients' glucose levels from a distance [2]. - DexCom's CGM technology eliminated the need for finger sticks, making diabetes management more convenient for users [2]. - The first CGM available over the counter was introduced by DexCom, increasing accessibility for patients [2]. Group 2: Clinical Data and Coverage - DexCom has paired its innovations with robust clinical data and randomized controlled trials, which have facilitated access and coverage for CGM technology for millions globally [2].

Summary of GE HealthCare Technologies FY Conference Call Company Overview - **Company**: GE HealthCare Technologies (NasdaqGS:GEHC) - **Focus**: Transitioning from a world-class imaging company to a comprehensive healthcare solutions provider, emphasizing precision care, growth acceleration, and business optimization [2][3] Core Strategies - **Precision Care**: Enhancing individual care through advanced imaging, diagnostics, and therapeutics [3] - **Growth Acceleration**: Focused on product innovation and market selection to drive faster growth [3] - **Business Optimization**: Aiming for agility and flexibility in operations, including margin expansion and inorganic integration [3][4] Financial Performance and Projections - **2025 Expectations**: Anticipated mid-single-digit revenue growth, with a strong backlog and order growth supporting acceleration into 2026 [40] - **Long-term Goals**: Projecting high-teens to 20%+ adjusted EBIT and 90%+ free cash flow from 2026 to 2028 [26][27] Product Innovations - **New Product Launches**: Significant introductions at the Radiological Society of North America (RSNA) trade show, including: - Total body PET system (Omni) pending FDA approval [13] - Photon counting system (Photonova Spectra) utilizing Deep Silicon technology [14] - StarGuide GX for imaging radiopharmaceuticals [15] - Vivid Pioneer in cardiovascular ultrasound with heavy AI integration [16] - **AI Integration**: Leading the MedTech industry with 115 FDA authorizations for AI applications, enhancing product value and patient outcomes [6] Market Dynamics - **Nuclear Medicine Growth**: Strong potential in therapeutic and diagnostic applications, particularly with new products like Flyrcado for myocardial perfusion imaging, projected to exceed $500 million in sales by 2028 [18][49] - **China Market Outlook**: Anticipated mid-single-digit growth in China, with a pragmatic approach to recovery timelines [43][44] Inorganic Growth Strategy - **Acquisition of Intelerad**: A strategic tuck-in acquisition aimed at enhancing cloud-first AI capabilities in imaging, expected to close in the first half of 2026 [19][20] Operational Efficiency - **Lean Management System**: Implementation of the Heartbeat management system to drive continuous improvement and operational efficiency [11][24] - **Cost Management**: Focus on reducing variable costs and optimizing organizational structure to enhance agility and profitability [23][24] Capital Allocation - **Investment Focus**: Prioritizing organic investments in R&D and strategic M&A to fill portfolio gaps, with a disciplined approach to capital allocation [25][30] Conclusion - **Shareholder Value Creation**: Commitment to optimizing customer and patient value while delivering high returns to shareholders through a differentiated portfolio and disciplined execution [29][30]

Company Overview - Haemonetics is a global leader in plasma apheresis, operating in a $1 billion addressable market that is expected to grow at least in the mid-single digits [3] - The company emphasizes its strong position in the plasma apheresis market, which provides a durable source of EBITDA, attractive return on invested capital, and robust free cash flow [3] Growth Strategy - To accelerate growth and reduce volatility, Haemonetics has decided to diversify into attractive med-surg markets while avoiding competition with therapeutic category leaders [4] - The company aims to acquire and grow a portfolio of scalable, therapeutically agnostic enabling technologies in various medical and surgical areas [4]

Core Insights - Bunkerhill Health has announced the deployment of its Carebricks platform at the University of Texas Medical Branch (UTMB), enhancing AI workflows for care delivery across a health system with over one million patient visits annually [1] Company Developments - The implementation of the Carebricks platform signifies a shift from isolated AI initiatives to a comprehensive system-wide action plan at UTMB Health [1]

JP Morgan 44th Annual Healthcare Conference January 13, 2026 © 2026 Haemonetics Corporation Important Information Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expect ...